What's going on with the medical scene? Prozac is another drug besides Ritalin that is given to children with ADHD. Besides it's long history of side-effects, it's still available to the public. Another thing. Vioxx is back on the market. (Below) After it has reportedly killed 140,000 cases of heart disease: http://www.healthtalk.ca/vioxx_study_012505_37989.php
Journal Raises Fresh Concerns Over Antidepressants
*Gezondheid/Health | 22 Februari 2005 | 06:06:38
The British Medical Journal, which published results from three studies on selective serotonin re-uptake inhibitors (SSRIs), said the findings underlined the need for caution in using the medicines.
"How many people who turned to 'happy pills' would not have done so if they had been fully aware of the potential harm?" acting editor Kamran Abbasi wrote in an editorial.
One study, pooling results from 702 trials involving 87,000 patients, found a doubling of suicide attempts, although there was no increase in actual suicides.
A second analysis of 477 trials submitted by drug companies to regulators found weak evidence of an increased risk of self-harm but not of suicide, while a third study highlighted a raised risk among under-18s.
Concerns about the safety of SSRIs are not new and drugs including GlaxoSmithKline Plc's Seroxat - the most widely prescribed among the drug class in Britain - were banned from use in children in 2003.
The UK's Medicines and Healthcare Products Regulatory Agency said the latest studies in the BMJ had been taken into account when the regulator issued new guidelines on the use of SSRIs last December.
Those called for doctors to use antidepressants sparingly and, in most cases, to only prescribe the lowest recommended dose.
http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=7676410
WASHINGTON (CNN) - While the painkillers Celebrex, Bextra, and Vioxx significantly increase the risk of cardiovascular problems, the danger is not great enough to justify taking the drugs off the market, according to an advisory committee of the Food and Drug Administration.
The 32-member panel unanimously agreed that each drug "significantly increases the risk of cardiovascular events." But in a 31-1 vote, the panel decided the overall risk posed by Celebrex is not enough to require removing the drug from the U.S. market. The votes on Bextra and Vioxx were much closer.
Find just what you are after with the more precise, more powerful new MSN Search Try it now.